Alpha Tau widens pancreatic cancer trial to test alpha radiation with more chemo regimens
Alpha Tau expanded the IMPACT trial's chemotherapy backbone and raised enrollment to 40 as it targets initial safety results by year-end 2026.
Executive Summary
- Alpha Tau is heading toward its first safety readout for alpha-radiation therapy delivered inside a pancreatic tumor, a step beyond the skin-cancer setting where the platform has so far been tested.
- Regulators cleared a broader version of the trial this year, letting the company enroll more patients under an expanded chemotherapy combination rather than a single regimen.
- Because the primary measure is safety, not tumor response, the near-term readout will establish tolerability of combining radiation seeds with chemotherapy, not whether the combination shrinks tumors or extends survival.
- No trial in newly diagnosed pancreatic cancer shares Alpha Tau's interstitial alpha-particle mechanism, leaving this readout without a direct precedent to benchmark against.
The catalyst
Alpha Tau Medical Ltd. (Nasdaq: DRTS) is targeting initial results from its IMPACT (Intratumoral Pancreatic Alpha Combination Trial) study by the fourth quarter of 2026, with a stated window running from October 1 through December 31. The trial, registered as NCT06698458, tests Alpha DaRT, an interstitial alpha-particle radiation source implanted directly into the tumor, combined with chemotherapy in patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma. The company told shareholders in January 2026 that it expected patient accrual and data readouts across its pancreas, brain and skin-cancer programs during the year. Alpha+1Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple ...Jan 29, 2026Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic CancerNCT06698458
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
The registered primary endpoint is safety, measured as serious adverse events, not tumor response or survival. Secondary endpoints track the percentage of locally advanced tumors that become surgically resectable and the rate of complete or pain response. Patients start with up to four cycles of mFOLFIRINOX chemotherapy before DaRT seed implantation, and enrollment is capped at a tumor no larger than 5 centimeters in its longest diameter. That design means the year-end readout will establish whether adding interstitial alpha radiation to standard chemotherapy is tolerable in this population, a tolerability question, not a claim about efficacy. NCT06698458Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic CancerNCT06698458
The regulatory amendment
The FDA approved an investigational device exemption supplement in April 2026 that expanded the trial to include patients on gemcitabine plus nab-paclitaxel, alongside the original mFOLFIRINOX cohort, and raised planned enrollment. The trial's enrollment target grew from 30 to 40 patients, a 33% increase recorded in the registry on May 6, 2026. In an early-phase pilot study, an enrollment increase tied to a regulator-cleared protocol expansion reads as an operational broadening of the trial's dosing population, not a signal of trouble. Alpha+1Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple ...Jan 29, 2026Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic CancerNCT06698458
Competitive standing
Among trials in pancreatic adenocarcinoma, none shares Alpha DaRT's interstitial alpha-particle mechanism. The nearest modality precedent is Novartis's early-phase lutetium-based radiopharmaceutical Lu-DFC413, which uses a different target and delivery approach. The broader pancreatic cancer field is populated mostly by KRAS-targeted small molecules from sponsors including Revolution Medicines and Immuneering, mechanisms unrelated to DNA-damage-based radiation therapy. That leaves Alpha DaRT without a direct comparator in this indication: the readout will be judged against the trial's own safety bar, not against a rival's result.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.